Minerva Neurosciences to Host In-Person KOL Event to Discuss Roluperidone for Negative Symptoms of Schizophrenia
Key Highlights
- ➤Nov. 12 KOL event will discuss roluperidone’s schizophrenia negative-symptom opportunity
- ➤Phase 3 roluperidone trial update planned for Nov. 12 event
- ➤New analysis will address roluperidone’s efficacy and safety
- ➤Roluperidone remains investigational with no FDA-approved negative-symptom treatments
- ➤Roluperidone is in a confirmatory Phase 3 monotherapy trial
BURLINGTON, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that it will host an in-person and virtual event in New York on Thursday, November 12, 2026, at 10:00 AM ET featuring several key opinion leaders and company management focused on the opportunity for roluperidone in treating the negative symptoms of schizophrenia. For more details and to register for the event, click here.
The event will feature three leading experts in negative symptoms of schizophrenia, Christoph Correll, MD (Donald and Barbara Zucker School of Medicine at Hofstra/Northwell in New York; and Charité – University Medicine, Berlin), Brian Kirkpatrick, MD, MSPH (University of Arkansas for Medical Sciences) and Gregory Strauss, PhD (University of Georgia), who will join company management. Key topics to be discussed include new analysis that provides evidence supporting roluperidone’s efficacy and safety, an update on the Phase 3 clinical trial of roluperidone that is currently underway, as well as other company updates. A live question and answer session will follow the formal presentations.
Get started
Create a free account to read the full story.